EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eidos Therapeutics's Enterprise Value is $4,624.80 Mil.
Eidos Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2020 was $-85.42 Mil. Therefore, Eidos Therapeutics's EV-to-FCF for today is -54.14.
The historical rank and industry rank for Eidos Therapeutics's EV-to-FCF or its related term are showing as below:
EIDX'
s EV-to-FCF Range Over the Past 10 Years
Min: -82.78 Med: -41.52 Max: -15.81
Current: -50.43
During the past 4 years, the highest EV-to-FCF of Eidos Therapeutics was -15.81. The lowest was -82.78. And the median was -41.52.
EIDX's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.59
vs EIDX: -50.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Eidos Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Eidos Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Eidos Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eidos Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Eidos Therapeutics's EV-to-FCF falls into.
Eidos Therapeutics's current Enterprise Value is $4,624.80 Mil.
Eidos Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Eidos Therapeutics's PE Ratio for today is calculated as:
Eidos Therapeutics's share price for today is $122.21.
Eidos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eidos Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Eidos Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Eidos Therapeutics (Eidos Therapeutics) Business Description
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EIDX has been successfully added to your 